PENPenumbra Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Adam Elsesser

Location

California, USA

Exchange

NYSE

Website

https://penumbrainc.com

Summary

Penumbra, Inc.

Company Info

CEO

Adam Elsesser

Location

California, USA

Exchange

NYSE

Website

https://penumbrainc.com

Summary

Penumbra, Inc.

AI Insights for PEN
5 min read

Quick Summary

Penumbra, Inc. is a medical device company based in Alameda, California that designs, develops, manufactures, and markets products used mainly in neurovascular, vascular, and neurosurgical procedures. The company is best known for aspiration-based thrombectomy systems that help physicians remove blood clots from vessels, including in stroke and peripheral vascular cases. It also sells accessory devices, access tools, embolization products, and neurosurgical aspiration devices used to remove tissue and fluids. Its main customers are hospitals, stroke centers, interventional neuroradiologists, neurosurgeons, interventional radiologists, vascular surgeons, and other specialists performing minimally invasive procedures. Penumbra operates in the medical equipment industry and generates revenue from the sale of specialized, procedure-driven devices rather than from recurring consumer products or pharmaceuticals.

Strengths

•

Penumbra’s main strength is its focused expertise in aspiration-based medical devices for complex vascular and neurovascular procedures.

•

The company operates in markets where clinical performance, physician trust, and product reliability are critical, which can create barriers to entry for less established competitors.

•

Its revenue base benefits from exposure to serious medical conditions such as stroke and vascular clotting, where treatment demand is not purely discretionary.

•

The company is profitable, with Q3 2026 net income of about $34.8 million and operating income of about $41.0 million.

•

Penumbra also has a relatively low beta of 0.701, suggesting that its shares may be less volatile than some higher-beta growth stocks, although valuation risk remains significant.

Key Risks

•

Penumbra faces regulatory, clinical, competitive, and valuation risks.

•

Medical devices must meet strict safety and effectiveness standards, and any product recall, adverse event trend, or regulatory delay could hurt revenue and reputation.

•

Competitive pressure from companies such as Stryker, Medtronic, Johnson & Johnson, and Boston Scientific could limit market share gains or pressure pricing.

•

Hospital purchasing constraints, reimbursement changes, or lower procedure volumes could also weigh on growth.

What to Watch

In the most recent reported quarter, Penumbra generated $390.0 million in total revenue, indicating continued commercial activity across its medical device portfolio.
Gross profit was approximately $264.9 million, which suggests the company maintained a substantial gross margin typical of differentiated medical technology businesses.
Operating income was about $41.0 million, while net income was about $34.8 million, showing that the company remained profitable during the quarter.
Basic and diluted EPS were both reported at $0.88, giving investors a clear profitability benchmark to compare with future quarters.
The provided news feed did not include a specific Penumbra product launch, acquisition, partnership, or controversy during the quarter, so the most reliable quarterly events are the financial results and the continued operation of its thrombectomy and neurosurgical device businesses.

Price Drivers

•

Penumbra’s stock price is likely driven primarily by revenue growth, procedure volume, margins, and investor confidence in its thrombectomy and neurovascular franchises.

•

The company reported Q3 2026 operating revenue of about $390.0 million, gross profit of about $264.9 million, operating income of about $41.0 million, and net income of about $34.8 million.

•

Its valuation metrics are high, including a price-to-earnings ratio near 79.5, EV-to-revenue near 8.0, and EV-to-EBITDA near 59.2, so the market appears to be pricing in meaningful future growth.

•

Because the stock does not pay a dividend, shareholder returns depend mainly on capital appreciation and sustained earnings expansion.

•

Price movement can also be affected by FDA or international regulatory updates, clinical data, hospital purchasing trends, competitive product launches, interest-rate expectations, and broader investor appetite for high-growth medical technology stocks.

Recent News

•

The provided recent news feed does not appear to contain a direct company-specific announcement about Penumbra, Inc.

•

One item mentions Richards Packaging Income Fund acquiring DermapenWorld, but DermapenWorld is a microneedling and dermatological cosmetics business and should not be confused with Penumbra despite the partial name similarity.

•

The other listed articles focus mostly on unrelated companies and themes, including Palantir, Procter & Gamble, Pfizer, utilities, AI power demand, and energy infrastructure.

•

Therefore, there is no clear evidence in the supplied news set of a recent Penumbra acquisition, partnership, controversy, or product launch.

•

In the absence of direct news, investors would likely rely more heavily on Penumbra’s reported financial metrics, upcoming earnings, and broader medical device sector trends.

Market Trends

•

Penumbra is affected by broader trends in medical technology, including the shift toward minimally invasive procedures and devices that improve procedural speed and outcomes.

•

Demand for stroke and vascular intervention tools may benefit from aging populations, better diagnosis, improved emergency response systems, and increasing physician adoption of endovascular treatment.

•

At the same time, hospitals are under cost pressure, so device companies must demonstrate clinical and economic value to maintain pricing and win purchasing decisions.

•

Higher interest rates or reduced investor appetite for growth stocks can pressure richly valued medical technology companies, even when operating performance remains solid.

•

The market also rewards companies that show durable revenue growth, improving margins, strong clinical evidence, and a credible pipeline of next-generation products.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on PEN

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@Ethancollins 2 days ago

Boston Scientific Raises Billions to Finance Its Big Penumbra Acquisition

Boston Scientific Raises Billions to Finance Its Big Penumbra Acquisition

Boston Scientific is making a major move in the debt market, pricing $3 billion in US dollar-denominated senior notes alongside another €4.25 billion in euro-denominated notes.

The bigger story is where that money is going. The company plans to use the proceeds, along with cash and additional borrowing, to help finance its proposed acquisition of Penumbra . The deal was valued at approximately $14.5 billion when announced.

What caught my attention is the scale of the financing. Boston Scientific is taking on a substantial funding commitment to expand its medical technology business, and the acquisition could strengthen its position in areas such as vascular and neurovascular treatments.

But there’s a risk investors shouldn’t overlook. More borrowing means additional interest costs, and the company will need to make sure the acquisition delivers enough long-term value to justify the investment.

Personally, I see the strategic opportunity, but execution and debt management will be just as important as the deal itself.

Do you think the Penumbra acquisition will be worth the financial commitment for Boston Scientific, or is the company taking on too much debt?

avatar
@BarnaclesActiv 10 months ago

Market recap: TSMC and banks lead recovery, oil drops 4%

Market recap: TSMC and banks lead recovery, oil drops 4%

post thumbnail

No more topics to show